Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study

Abstract

Background There is limited data on outcomes of moderate to severe Coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting. Objective To compare the effectiveness of standard of care (SOC) alone vs SOC plus remdesivir and dexamethasone. Methods Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI). Results The 30-d mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI, 0.38-0.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36 (95% CI, 0.29-0.46)). Conclusions and relevance Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.

Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent

“…The combination may treat the viral infection and dampen the potentially injurious inflammatory response that is a consequence of the infection. However, the data on clinical outcomes for patients who received this combination are currently limited [ 50 ]. If dexamethasone isn't accessible, other corticosteroids like prednisone, methylprednisolone or hydrocortisone can be used in place of it.…”

Dexamethasone ameliorates severe pneumonia but slightly enhances viral replication in the lungs of SARS-CoV-2-infected Syrian hamsters

“…The hyperactivated and dysregulated immune system in critical cases necessitates anti-inflammatory immunotherapy [ 3 ]. Recently, several clinical studies demonstrated that the FDA-approved glucocorticoid drug dexamethasone is able to reduce disease severity and mortality in hospitalized human patients with SARS-CoV-2 infection [ 4 , 5 ]. In contrast to newly developed drugs, dexamethasone has unique advantages, including being inexpensive and widely available and having 60 years of safety profiling [ 6 ].…”

Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning

“…Similarly, including the pandemic week in which a patient had their FPT as a feature revealed that patients early rather than later in the pandemic, had a higher risk of dying. As our data covered both the first and second pandemic wave in Denmark, this finding likely reflects that our model captured improvements in the clinical management of patients throughout the pandemic 54 .…”